![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
Active Clinical Trials
September 30, 2021
This phase II trial is exploring the targeted cancer therapy gilteritinib, a tyrosine kinase inhibitor that kills leukemia cells by binding to the mutant FLT3 protein and blocking its activity
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
August 17, 2021
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
August 17, 2021
This study is evaluating two different screening strategies for non-cancerous pancreatic cysts; recently activated amendment #2 expands the eligibility criteria
August 17, 2021
This phase II trial is comparing adjuvant treatment with either reirradiation plus pembrolizumab, pembrolizumab monotherapy, or reirradiation with platinum chemotherapy
July 7, 2021
Could a culturally-sensitive app help improve endocrine therapy medication adherence in Hispanic/Latina patients undergoing breast cancer treatment?
July 7, 2021
Recent ECOG-ACRIN trial updates and results
July 7, 2021
This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
July 7, 2021
This phase II study will test the effect of nivolumab plus ipilimumab, with short-course radiation, for the neoadjuvant treatment of patients with low-lying, locally advanced MSI-H/dMMR rectal cancer
July 7, 2021
The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
May 28, 2021
This phase II study, led by Dr. Kim Reiss Binder, is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
May 28, 2021
The EA8185 phase II trial is the first prospective study exclusively for patients with lymph node positive bladder cancer